-
公开(公告)号：EP1045908A2
公开(公告)日：2000-10-25
申请号：EP99902140.5
申请日：1999-01-08
申请人： SMITHKLINE BEECHAM CORPORATION , SMITHKLINE BEECHAM PLC , Smithkline BeechamLaboratoires Pharmaceutiques
发明人： CULP, Jeffrey, S. , MCNULTY, Dean, E. , ELLIS, Catherine, E. , DOUGLAS, Stephen, A.,B202 La Maison Apartments , WILLETTE, Robert, N. , AIYAR, Nambi, V. , ARNOLD, Anne, Romanic , KHANDOUDI, Nassirah , GOUT, Bernard , AL-BARAZANJI, Kamal
IPC分类号： C12N15/16 , C07K14/575 , C07K16/26 , A61K48/00 , A61K38/22 , C12Q1/68 , G01N33/68 , C12N15/11
CPC分类号： G01N33/74 , A61K38/00 , A61K48/00 , A61K2039/51 , C07K14/57509 , G01N33/6893
摘要： Human Urotensin II polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Human Urotensin II polypeptides and polynucleotides in therapy, and diagnostic assays for such.
-
2.发明公开HUMAN RECEPTOR GPR14, AND A METHOD OF FINDING AGONIST AND ANTAGONIST TO HUMAN AND RAT GPR14 审中-公开人类受体GPR14和方法用于搜索激动剂和拮抗剂人和大鼠GPR14受体
公开(公告)号：EP1056844A1
公开(公告)日：2000-12-06
申请号：EP99903409.3
申请日：1999-01-27
申请人： SMITHKLINE BEECHAM CORPORATION , SMITHKLINE BEECHAM PLC , Smithkline BeechamLaboratoires Pharmaceutiques
发明人： DOUGLAS, Stephen, A.,B202 La Maison Apartments , WILLETTE, Robert, N. , AIYAR, Nambi, V. , ARNOLD, Anne, Romanic , KHANDOUDI, Nassirah , GOUT, Bernard , AL-BARAZANJI, Kamal , AMES, Robert, S. , FOLEY, James, J. , SARAU, Henry, M. , CHAMBERS, Jon , SHABON, Usman , BERGSMA, Derk, J.
CPC分类号： C07K14/705 , A61K38/00 , A61K48/00 , C07K14/723
摘要： Human GPR14 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Human GPR14 polypeptides and polynucleotides in the design of protocols for the treatment of ischemic coronary artery disease (angina and myocardial infarction); atherosclerosis; metabolic diseases (e.g. diabetes); CHF/myocardial dysfunction; arrhythmias; restenosis; hypertension; hypotension; pulmonary disease (hypertension, COPD, asthma); fibrotic vasculopathies (diabetes, SLE, AS, Reynaud's); cerebrovascular events (e.g. hemnorrhagic and ischemic stroke); neurogenic inflammation/migraine; hematopoietic disorders; ARDS; cancer; autoimmune diseases (e.g. HIV-1 and -2 infection and AIDS); gastrointestinal and genitourinary disturbances (e.g. ulcers); endocrine disorders; fibroproliferative disorders (e.g. psoriasis); inflammatory disease (e.g. RA, Crohn's, IBS); benign prostatic hypertrophy; renal failure and glomerulopathies; disease states, both cardiovascular and non-cardiovascular, which are characterized by excessive vasoconstriction, myocardial dysfunction and/or aberrant fibroproliferative/inflammatory responses; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation, Parkinson's disease, and dyskinesias, infections such as bacterial, fungal, protozoan and viral infections; pain; eating disorders, such as obesity, anorexia, and bulimia; asthma; urinary retention; oteoporosis; allergies; Huntington's disease or Gilles de la Tourette's syndrome, among others and diagnostic assays for such conditions.
-
公开(公告)号：EP1385504B1
公开(公告)日：2008-12-17
申请号：EP02733968.8
申请日：2002-04-10
发明人： WILLETTE, Robert, N.
CPC分类号： A61K31/55
摘要： This invention relates to the use of a vitronectin receptor antagonist to inhibit adhesion formation.
-
公开(公告)号：EP1385504A1
公开(公告)日：2004-02-04
申请号：EP02733968.8
申请日：2002-04-10
发明人： WILLETTE, Robert, N.
IPC分类号： A61K31/35
CPC分类号： A61K31/55
摘要： This invention relates to the use of a vitronectin receptor antagonist to inhibit adhesion formation.
-
-
-
搜索结果
4 条记录 (耗时 0.015 秒)
